Stem cell therapy has emerged as a potential therapeutic option for cell death-related heart diseases. Preclinical and a number of early phase human studies suggested that cell therapy may augment perfusion and increase myocardial contractility. The rapid translation into clinical trials has left many issues unresolved, and emphasizes the need for specific techniques to visualize the mechanisms involved. Furthermore, the clinical efficacy of cell therapy remains to be proven. Imaging allows for in vivo tracking of cells and can provide a better understanding in the evaluation of the functional effects of cell-based therapies. In this review, a summary of the most promising imaging techniques for cell tracking is provided. Among these are direct labeling of cells with super-paramagnetic agents, radionuclides, and the use of reporter genes for imaging of transplanted cells. In addition, a comprehensive summary is provided of the currently available studies investigating a cell therapy-related effect on left ventricular function, myocardial perfusion, scar tissue, and myocardial viability. (J Am Coll Cardiol 2007;49:1137-48)
Stem cell transplantation is being widely investigated as a potential therapy for cell death-related heart diseases (1). Several cell types, including embryonic stem cells (2) , skeletal myoblasts (3, 4) , bone marrow-derived cells (5-7), or cardiac resident stem cells (8, 9) , are being tested, and preclinical studies have shown the potential of various approaches to repair acutely or chronically damaged myocardium.
In some experimental settings, transplantation of stem or progenitor cells after myocardial infarction reduces scar formation and fibrosis, and preserves cardiac function. Moreover, different subsets of progenitor cells were shown to augment perfusion. Both observations may be related to a direct physical effect (differentiation of progenitor cells to endothelial cells, smooth muscle cells, and cardiomyocytes) and/or to the release of paracrine factors by progenitor cells, which prevent apoptosis of cardiomyocytes, modulate scar development, or promote angiogenesis (1) .
On the basis of these encouraging preclinical studies, there is a growing number of early phase human studies that aim to demonstrate the feasibility and potential efficacy of cell-based therapies in the clinical setting (10 -35) . This rapid translation into clinical studies has left a lot of questions concerning cell therapy unanswered. For example, the optimal cell type, the number of cells to be delivered, the most suitable route for cell delivery, and the optimal time point for cell delivery after myocardial infarction are unknown. Furthermore, the biodistribution of the therapeutic cells after delivery and the specific mechanism by which therapeutic cells contribute to functional improvement remain to be investigated. Imaging is crucial for in vivo tracking of cells and better understanding and evaluation of the effects of cell therapy. In this review, we have attempted to summarize the available evidence on imaging of cell therapy.
Cell Tracking by Use of Noninvasive Imaging
The ideal imaging modality should provide integrated information related to the entire process of cell engraftment, survival, and functional outcome. Clinically established parameters of noninvasive imaging, such as contractile function, perfusion, and viability of the myocardium, do not provide direct visualization of transplanted cells, their biology or function. Thus, a number of contrast agents and detectors for noninvasive, repeatable visualization of therapeutic cells in vivo have been pursued (36) . Such imaging approaches may not only refine the understanding of therapeutic mechanisms in preclinical studies but may also have direct clinical applications. Most of the available cellular molecular imaging techniques are also applicable in humans, and therefore may facilitate rapid translation of cell-based therapies into clinical practice. Table 1 and Figure 1 summarize labeling strategies for in vivo surveillance and tracking of various cell populations.
Radionuclide technology and magnetic resonance imaging (MRI) are best suited to meet such broad objective thanks to their resolution and clinical applicability, with MRI having some advantages in terms of spatial resolution (Table 2 ). Cells can be labeled directly with super-paramagnetic iron oxide agents or radionuclides before their application for subsequent in vivo visualization of their distribution. Additionally, genetic labeling with reporter genes that can be traced with imaging probes has been introduced, which will allow for repeatable tracking of cellular and subcellular function over a longer period of time. The use of non-invasive imaging modalities in preclinical cell therapy studies revealed key aspects of cell biology that will not be observed by other approaches except for histologic analysis. In particular, the ability to dynamically follow cell trafficking and survival over longer periods of time contributed to the understanding of the potential mechanism of benefit. Direct labeling of cells using magnetic resonance agents. Magnetic resonance imaging has become a key surrogate end point to demonstrate efficacy in early phase, small-sized studies (37) . Magnetic resonance imaging can provide detailed morphologic and functional information and, therefore, seems ideally suited to integrate efficacy assessments with the capability for cell tracking. The potential for assessing engraftment of therapeutic cells was quickly realized, and investigations are now focusing on refining contrast agents to ensure maximum signal for minimum labeling. Initial animal model studies using micron scale particles (38, 39) or nanoparticles of iron oxide (40, 41) showed the potential for non-toxic labeling of hematopoietic bone marrow-derived and mesenchymal stem cell populations without affecting their transdifferentiation capacity. In the cardiovascular setting, this cell labeling technology was coupled with direct delivery methods using endomyocardial injections, demonstrating that transplanted cells could be imaged shortly after delivery with a high degree of spatial resolution using MRI (40) (Fig. 2) . Iron oxide labeling can also be used to track smaller numbers of cells in homing experiments allowing for in vivo identification of mesenchymal stem cells that migrated to infarcted myocardium after intravenous administration (41) . Yet, in the studies described in the preceding text, the lowest detectable number of cells was 10 5 with the use of conventional MRI scanners without any sequence modification. This threshold of detection can be lowered using high-field magnets (11.7-T) such that single cells containing a single iron particle can be detected and tracked (42) .
There are potential theoretical disadvantages to the use of magnetic labeling. Most importantly, the imaging signal is not directly linked with cell viability. There is a risk for release of iron oxide after cell death and its accumulation in bystander cells confounding any quantitative assessment of cell trafficking. In addition, cell division can dilute the magnetic label within only a few cell divisions. Novel direct labeling techniques like Clio-tat peptides (43) or magnetic relaxation switches (44) are under development in preclinical studies and could help overcome some of these limitations in the future. Despite minimal effect of iron oxide particles on in vitro proliferative capacity and cell viability (38) , there are recent data raising concern about the impact on the differentiation capacity of mesenchymal stem cells along a chondrogenic differentiation pathway (45) . On the other hand, this effect may be compound specific, because the 2 Food and Drug Administration-approved iron oxidebased agents affect neither hematopoietic nor mesenchymal stem cell function or differentiation capacity (46) . Before clinical application, future work is required to investigate the effect of iron-labeling on stem cell proliferation and differentiation.
Techniques for In Vivo Imaging of Labeled Transplanted Cells (Fig. 3 ), but the overall radioactivity in the heart was only around 4.7% of the injected dose (47) . These data suggest that only a small number of cells ultimately home to injured myocardium, but they also corroborate the high sensitivity of the nuclear imaging technique. In another study using In-111-labeled mesenchymal stem cells in pigs, accumulation in the lungs was observed early after intravenous injection, which was found to obscure assessment of myocardial cell trafficking (48) . This observation was confirmed in rats by another group, using technetium (Tc)-99m exametazime (HMPAO) for labeling of bone marrow-derived mesenchymal stem cells and observing entrapment of the donor cells in the lungs (49) . More recently, homing of In-111-labeled mesenchymal stem cells to infarcted myocardium was successfully visualized in a dog model using single-photon emission computed tomography (SPECT)-CT (41) . Finally, the positron emission tomography (PET) tracer F18-fluorodeoxyglucose (F18-FDG) has been used for labeling and imaging of bone marrow cells in humans. Myocardial accumulation of cells was demonstrated after intracoronary infusion, but not after intravenous delivery. With immunomagnetically enriched CD34-positive cells, 14% to 39% of total injected radioactivity was detected in infarcted myocardium after intracoronary injections, preferentially in the border zone (50) . Other data indicate that radiolabeling could be used to assess early kinetics after cell injection.
Figure 1 Approaches for Cell Tracking by Noninvasive Imaging
Cells are labeled directly for magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), or with a reporter gene for subsequent reporter-gene imaging using either of the techniques. F18-FDG ϭ fluorodeoxyglucose; HMPAO ϭ exametazime; IFP ϭ iron fluorescent particle; SPIO ϭ super-paramagnetic iron oxide; Tc ϭ technetium.
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Tc-99m-HMPAO-labeling of mononuclear cells indicated that cardiac engraftment of cells is a dynamic process: the radioactivity uptake by the heart was 5% at 2 h and 1% at 18 h after transcoronary cell transplantation in a patient with acute myocardial infarction (51) . These data support the translational potential of nuclear imaging to guide cell therapy approaches from preclinical to clinical applications and to provide mechanistic information in applications like intracoronary administration with higher sensitivity than MRI. Future work should aim to prolong the half-life time of radioisotopes in order to prevent loss of the imaging signal within a few days.
Reporter genes for cardiovascular cell imaging. The usefulness of reporter genes for imaging of gene transfer to the myocardium has been established recently (52) . This principle may be expanded to imaging of cell-based therapies. A reporter gene of choice can be transferred to cells for genetic labeling, before their in vivo administration. After application, cells can then be detected by an intravenously administered, radio-labeled or optical reporter probe, which is specific for the reporter gene and which accumulates solely in the transduced therapeutic cells (Fig. 4) . Because accumulation of the reporter probe requires expression of the reporter gene and activity of the reporter-gene product, the imaging signal will be dependent on viability of the therapeutic cells. This is in contrast with direct "passive" labeling techniques and provides a more specific readout. Additionally, imaging can be performed repeatedly and is not limited by radioactive decay of the initial label load. Observation of genetically labeled cells is thus possible over a long period of time, and may only be limited by epigenetic silencing (53) . Proof of principle for imaging of genetically labeled cells was obtained using rat cardiomyoblasts, which were infected ex vivo with adenovirus carrying the HSV1-sr39tk and luciferase reporter genes. Cell-specific in vivo optical and micro-PET imaging was feasible for up to 2 weeks after direct injection of cells into the myocardium of nude rats. For optical imaging, 5 ϫ 10 5 cells were detectable, while PET images were obtained using 3 ϫ 10 6 cells (54). Subsequent preclinical studies used reporter-gene labeling to demonstrate usefulness of novel intramyocardial injection techniques and assess cell survival, proliferation, and migration over a longer period of time (55, 56) . Importantly, genetic labeling also holds promise to provide insights into subcellular mechanisms that take place within therapeutic cells. Reporter genes may be expressed under control of restrictive promoters that are sensitive to certain endogenous molecules. Despite bearing a conceptual promise, the use of reporter-gene imaging to monitor cell transplantation is still limited to animal model studies. In order to proceed from bench to bedside, further work is required to develop nonimmunogenic probes, improve transfection stability, and reduce the interference of transfection with the cell function and desired molecular effect. Strength of the imaging signal is critical, and additional work is necessary to establish a robust approach for cell visualization that is also practical for use in the clinical setting.
Imaging to Evalute Functional Effects of Cell Therapy
Imaging may be particularly helpful in evaluating the functional effects of cell therapy. The various clinical studies have mainly focused on detection of differences in left ventricular (LV) function, myocardial perfusion, infarct size, and myocardial viability. Table 3 summarizes the 17 available studies (including 10 or more patients) that have evaluated changes in LV function after cell therapy. In total, 526 patients underwent cell therapy in these studies. Ten studies were performed in the setting of acute myocardial infarction, and 7 studies were performed in the setting of chronic ischemic heart disease. Assessment of function was performed ranging from 3 to 18 months after cell therapy.
LV function.
Ten studies showed an improvement in LV ejection fraction (LVEF), indicating improved systolic function. The majority of studies indicated small improvements in LVEF (range 2.9% to 9.3%), but Chen et al. (19) demonstrated in 34 patients with acute myocardial infarction an improvement of 18%. Different techniques were used to assess LV function and volumes, including LV angiography, 2-dimensional echocardiography, gated SPECT, radionuclide ventriculography, and MRI. The most accurate assessment of LVEF and LV volumes is MRI, and Fernández-Avilés et al. (18) demonstrated an increase of 5.8% in LVEF as assessed by MRI, whereas no improvement was seen in control patients. The global improvement of LVEF was mainly related to an improvement of regional LV function in the infarct zone, although improvement of function in the infarction border zone has also been reported. Left ventricular end-diastolic volume (LVEDV) remained unchanged in most (12 of 17) studies, indicating absence of LV reverse remodeling. However, since LVEDV did not increase either, one could argue that cell therapy prevented progressive LV dilatation. In support of this, Bartunek et al. (20) demonstrated that the LVEDV index remained unchanged in patients undergoing cell therapy, whereas an increase from 91 Ϯ 7 ml/m 2 to 103 Ϯ 9 ml/m 2 (p Ͻ 0.05) was observed in control patients. The improvement of LVEF may be a time-dependent process; in the BOOST (BOne marrOw transfer to enhance ST-segment elevation infarct regeneration) trial, sequential measurements were performed in 30 bone marrow cell transfer patients and in 30 control patients, at 6 and 18 months. At 6 months, MRI demonstrated an increase in LVEF of 6.7% in bone marrow cell transfer patients, as compared with 0.7% in control subjects (p Ͻ 0.01). However, at 18 months, the LVEF change was not significantly different between the 2 groups (ϩ5.9% vs. ϩ3.1%; p ϭ NS). Analysis of the time course of LVEF improvement, however, revealed a significantly faster recovery of LVEF in the bone marrow cell transfer patients than in control patients (p Ͻ 0.01) (17) . Myocardial perfusion. A total of 11 studies (including 239 patients) evaluated the effect of cell therapy on perfusion (Table 4) . Five studies were performed in the setting of PET ϭ positron emission tomography; Tc ϭ technetium; Tl ϭ thallium; other abbreviations as in Table 3 .
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Effect of Cell Therapy on LV Function and Volumes

Effect of Cell Therapy on Myocardial Perfusion
acute myocardial infarction, 3 studies in patients with chronic infarction, and 3 studies in patients with stressinduced ischemia. Assessment of perfusion was performed ranging from 3 to 12 months after therapy. The clinically available tools for assessment of myocardial perfusion include nuclear imaging with PET or SPECT, MRI using first-pass perfusion, or myocardial contrast echocardiography. In addition, coronary blood flow can invasively be assessed using the Doppler flow wire at rest and during pharmacologic stress. Subsequent calculation of the coronary flow reserve provides insight into the integrity of both the epicardial conduit arteries and the distal microvascular bed. In 9 of 11 currently available studies, SPECT was used, and only Janssens et al. (21) used PET to evaluate the effect of cell therapy on perfusion. It should be emphasized, however, that only PET permits absolute quantification of myocardial perfusion, whereas SPECT provides information on relative changes in tracer uptake.
The majority (10 of 11) of studies demonstrated some effect of cell therapy on perfusion. For example, Bartunek et al. (20) , using resting Tc-99m sestamibi SPECT, demonstrated a decrease in resting perfusion defect size at 4 months. Conversely, defect size did not change in control patients. Similar results were reported by other groups. Of note, the only study with PET could not demonstrate an increase in perfusion (21) .
The majority of the studies evaluated only resting perfusion, but few studies evaluated both rest and stress perfusion with SPECT. Beeres et al. (31) demonstrated in patients with refractory angina a significant decrease in the number of segments with stress-inducible ischemia. A patient example with a reduction in ischemia is shown in Figure 5 .
Perin et al. (33) presented similar results with stress-rest Tc-99m sestamibi SPECT in heart failure patients.
Three studies used intracoronary Doppler with 2 of 3 studies showing an improvement in coronary flow reserve. For example, a substudy of the TOPCARE-AMI (Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction) trial revealed that progenitor cell therapy was associated with complete restoration of coronary flow reserve due to a substantial improvement of maximal coronary vascular conductance capacity (15) . Infarct size. In the clinical setting, 12 studies (including 355 patients) evaluated the effect of cell therapy on infarct size (Table 5) . Seven studies were performed in the setting of acute infarction, whereas 5 were performed in patients with chronic infarction. Assessment of scar tissue was performed ranging from 3 to 18 months after therapy. A variety of techniques is available to assess infarct size, including techniques that directly visualize the scar tissue (i.e., nuclear imaging with PET or SPECT, contrastenhanced MRI, myocardial contrast echocardiography), or indirect approaches that visualize the extent and severity of LV dysfunction (LV angiography, 2-dimensional echocardiography, or cine MRI). Eight studies evaluated infarct size with SPECT or contrast-enhanced MRI, whereas 4 studies evaluated systolic dysfunction in the infarct zone as an indicator of extent of scar tissue. Seven of 12 studies demonstrated some reduction in infarct size, both in the setting of acute and chronic infarction.
The most accurate technique is contrast-enhanced MRI, allowing precise detection of scar tissue and currently the only technique discriminating between subendocardial and transmural infarction (57) . In the BOOST trial, contrast- Tables 3 and 4. enhanced MRI was performed at baseline, at 6 and 18 months follow-up. At 18 months, a mean reduction in infarct size of 13 Ϯ 12 ml was demonstrated in patients undergoing cell therapy, but control patients exhibited a comparable reduction in infarct size (10 Ϯ 13 ml; p ϭ NS vs. patients undergoing cell therapy) (17) . Of note, Ingkanisorn et al. (58) recently demonstrated a significant reduction in infarct size on contrast-enhanced MRI performed at 1.7 Ϯ 0.8 days and 2 months after acute myocardial infarction. Clearly, randomized controlled trials are needed to evaluate changes in infarct size after cell therapy as compared with the natural evolution after reperfused acute infarction. Myocardial viability. A total of 10 studies (in 243 patients) evaluated changes in viability after cell therapy (Table 6 ). Six studies were performed in the setting of acute infarction, 2 studies after chronic infarction, and 2 studies in patients with stress-induced ischemia. Follow-up ranged from 3 to 6 months after cell therapy. The clinically available techniques for evaluation of viability include nuclear imaging with PET (mainly using F18-FDG, evaluating glucose utilization) or SPECT (with F18-FDG or Tc-99m-labeled agents), or low-dose dobutamine echocardiography (assessing contractile reserve). Contractile reserve can also be assessed by low-dose dobutamine MRI. Non-fluoroscopic catheter-based electromechanical mapping enables identification and localization of viable myocardial tissue by simultaneous assessment of electrical activation and local mechanical response.
Five studies used F18-FDG PET or SPECT to evaluate viability in the infarct zone of which 4 reported an increased F18-FDG uptake after cell therapy. For example, in the IACT (Regeneration of Human Infarcted Heart Muscle by Intracoronary Autologous Bone Marrow Cell Transplantation in Chronic Coronary Artery Disease) study, a mean increase of 15% in F18-FDG uptake in the infarct zone was demonstrated (25) . Similarly, in the TOPCARE-AMI study, mean F18-FDG uptake in the infarct zone increased from 55% to 58% at 4 months; however, data on control patients were not available (14) .
Three studies used low-dose dobutamine echocardiography with 2 of 3 studies showing no improvement in contractile reserve, in contrast with the improvement observed in viability studies using F18-FDG PET. It should be noted that F18-FDG imaging reflects glucose utilization, whereas low-dose dobutamine echocardiography detects contractile reserve. Although both parameters are markers of myocardial viability, not all viable myocardium may exhibit both contractile reserve and preserved glucose utilization. In patients with severely dysfunctional myocardium and extensive damage on the cellular level, contractile reserve is frequently lost, whereas glucose utilization is preserved (59) . Additional studies, evaluating different features of viable myocardium in the same patients, are needed to elucidate changes in myocardial viability after cell therapy.
Effect of Cell Therapy on Myocardial Viability Table 6 Effect of Cell Therapy on Myocardial Viability Table 3 .
